


A COMPREHENSIVE TEXT

Edited by


CEDRIC S. RAINE

HENRY F. McFARLAND

REINHARD HOHLFELD




Merck 2004 Hopewell v Merck



SAUNDERS ELSEVIER







Multiple Sclerosis: A Comprehensive Text

WL 360 M95595

Edited by

Cedric S. Raine PhD DSc FRCPath


Professor, Departments of Pathology (Neuropathology), Neurology and Neuroscience, Albert Einstein College of Medicine, New York, USA

Henry F. McFarland MD

Chief, Neuroimmunology Branch, and Clinical Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

Reinhard Hohlfeld MD

Professor and Director of the Institute for Clinical Neuroimmunology, Ludwig-Maximilians University, Klinikum Grosshadern, Institute for Clinical Neuroimmunology, Munich, Germany



EDINBURGH LONDON NEW YORK OXFORD PHILADELPHIA ST LOUIS SYDNEY TORONTO 2008





An imprint of Elsevier Limited

© 2008, Eisevier Limited. All rights reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the Publishers. Permissions may be sought directly from Elsevier's Health Sciences Rights Department, 1600 John F. Kennedy Boulevard, Suite 1800, Philadelphia, PA 19103-2899, USA: phone: (+1) 215 239 3804; fax: (+1) 215 239 3805; or, e-mail: healthpermissions@elsevier.com. You may also complete your request on-line via the Elsevier homepage (http://www.elsevier.com), by selecting 'Support and contact' and then 'Copyright and Permission'.

ISBN 978-0-7020-2811-3

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging in Publication Data

A catalogue record for this book is available from the Library of Congress

Note

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on their own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors assume any liability for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this book.

The Publisher

Working together to grow libraries in developing countries www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID

Sabre Foundation



your source for books, journals and multimedia in the health sciences

www.elsevierhealth.com

publisher's policy is to use paper manufactured from sustainable forests

Printed in China




Preface

Why another book on multiple sclerosis? To us, the reason was obvious - the terrain of multiple sclerosis (MS) is vast and ever-changing. So much is happening that concepts forged just 2 years ago are already passé. Whether viewed from the platform of the health professional responsible for the day-today care of the patient or the scientist working to unravel what makes this a unique disease, MS has over the last decade evolved into a condition necessitating multidisciplinary approaches to both its management and understanding. One needs only to peruse the profiles of the personnel associated with an MS care center (particularly one located in an academic setting) to appreciate the enormous array of skills and treatments now available to the patient. For the scientific investigator, the rapidity of developments in recent years has been quite intimidating as genetics, immunology and molecular biology have assumed center stage, a fact reflected daily in our language, tools and techniques. In short, MS is a moving target and, as a consequence, we need to keep adjusting our sights. This book is the

Why a 'comprehensive' textbook? In the past, authors of texts on MS have shied away from broad-fronted coverage, with the preface of one renowned 1985 tome announcing 'it is no longer possible even to attempt a comprehensive work on mul-

tiple sclerosis'. If that were the case 20-plus years ago when the number of treatments for the MS patient was virtually zero and the diagnostic tools and research options were limited (to say the least), imagine the scope of the endeavor today! We have for certain come a long way since the 1980s - just look how much is out there now for the patient! With more than half-a-dozen approved and effective drugs specifically designed for MS, and dozens in advanced stages of clinical trials and/or awaiting approval, there is a wealth of new information to report. Thus, because the horizon is brighter than ever before for those affected with or involved in the condition, we think the time is ripe for a fresh look at the status of MS as a clinical problem, for the latest coverage on expanding prospects for the patient, and for a state-of-the-art re-evaluation of changes occurring within the nervous system. Since any approach to MS, scientific or care-related, is almost guaranteed to embrace the combined skills of several disciplines, for an individual to embark single-handed upon the preparation of a text on the subject might understandably be deemed over-ambitious. Therefore, fully cognizant of the challenge and somewhat intimidated by recently published excellent works on the subject, the present Anglo-American-German editorial alliance was assembled, each editor having one foot firmly planted in MS and the other in a



Cedric S. Raine, New York City, NY, USA



Henry F. McFarland, Washington, DC, USA



Reinhard Hohlfeld, Munich, Germany

٧



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

